NCT07185880View on ClinicalTrials.gov

A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

June 30, 2027

Conditions
Glioblastoma (GBM)
Interventions
DRUG

MT-125

This is an investigational new drug under IND 170975.

Trial Locations (3)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

85054

Mayo Clinic, Phoenix

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

Myosin Therapeutics Inc.

INDUSTRY